Storia in 2 fonti

Braveheart, Attovia join next wave of biotech IPOs

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.

Raccontata da

biopharmadive.com

endpoints.news

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo9 g fa

Braveheart, Attovia join next wave of biotech IPOs

The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.

originale

endpoints.news8 g fa

Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival

Braveheart Bio files for a Nasdaq IPO to fund Phase 3 trials of heart drug BHB-1893, the fourth biotech IPO filing in two weeks.

Leggi questa versione → originale

Timeline cronologica

mercoledì 15 luglio 2026·biopharmadive.com
Braveheart, Attovia join next wave of biotech IPOs
The two startups are the third and fourth, respectively, to outline offerings this month and aim to capitalize on momentum that’s already yielded several big-ticket IPOs.
mercoledì 15 luglio 2026·endpoints.news
I&I startup Attovia files to go public as biotech listings momentum builds
Attovia files for a Nasdaq IPO under ticker ATTO, becoming the third biotech to file this month after Scribe and Apnimed.

Braveheart, Attovia join next wave of biotech IPOs

Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival

Timeline cronologica

Braveheart, Attovia join next wave of biotech IPOs

I&I startup Attovia files to go public as biotech listings momentum builds

Braveheart files for IPO to fund Phase 3 of Hengrui's Cytokinetics rival